Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefano Annunziato, Julian R. de Ruiter, Linda Henneman, Chiara S. Brambillasca, Catrin Lutz, François Vaillant, Federica Ferrante, Anne Paulien Drenth, Eline van der Burg, Bjørn Siteur, Bas van Gerwen, Roebi de Bruijn, Martine H. van Miltenburg, Ivo J. Huijbers, Marieke van de Ven, Jane E. Visvader, Geoffrey J. Lindeman, Lodewyk F. A. Wessels, Jos Jonkers
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/d9ac65cbd345403caaf37726c9a7d740
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d9ac65cbd345403caaf37726c9a7d740
record_format	dspace
spelling	oai:doaj.org-article:d9ac65cbd345403caaf37726c9a7d7402021-12-02T16:57:52ZComparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer10.1038/s41467-019-08301-22041-1723https://doaj.org/article/d9ac65cbd345403caaf37726c9a7d7402019-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-08301-2https://doaj.org/toc/2041-1723It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbation of candidate driver genes, validating drivers Myc, Met, Pten and Rb1, and identifying MCL1 as a collaborating driver whose targeting can impact efficacy of PARP inhibition.Stefano AnnunziatoJulian R. de RuiterLinda HennemanChiara S. BrambillascaCatrin LutzFrançois VaillantFederica FerranteAnne Paulien DrenthEline van der BurgBjørn SiteurBas van GerwenRoebi de BruijnMartine H. van MiltenburgIvo J. HuijbersMarieke van de VenJane E. VisvaderGeoffrey J. LindemanLodewyk F. A. WesselsJos JonkersNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Stefano Annunziato Julian R. de Ruiter Linda Henneman Chiara S. Brambillasca Catrin Lutz François Vaillant Federica Ferrante Anne Paulien Drenth Eline van der Burg Bjørn Siteur Bas van Gerwen Roebi de Bruijn Martine H. van Miltenburg Ivo J. Huijbers Marieke van de Ven Jane E. Visvader Geoffrey J. Lindeman Lodewyk F. A. Wessels Jos Jonkers Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
description	It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbation of candidate driver genes, validating drivers Myc, Met, Pten and Rb1, and identifying MCL1 as a collaborating driver whose targeting can impact efficacy of PARP inhibition.
format	article
author	Stefano Annunziato Julian R. de Ruiter Linda Henneman Chiara S. Brambillasca Catrin Lutz François Vaillant Federica Ferrante Anne Paulien Drenth Eline van der Burg Bjørn Siteur Bas van Gerwen Roebi de Bruijn Martine H. van Miltenburg Ivo J. Huijbers Marieke van de Ven Jane E. Visvader Geoffrey J. Lindeman Lodewyk F. A. Wessels Jos Jonkers
author_facet	Stefano Annunziato Julian R. de Ruiter Linda Henneman Chiara S. Brambillasca Catrin Lutz François Vaillant Federica Ferrante Anne Paulien Drenth Eline van der Burg Bjørn Siteur Bas van Gerwen Roebi de Bruijn Martine H. van Miltenburg Ivo J. Huijbers Marieke van de Ven Jane E. Visvader Geoffrey J. Lindeman Lodewyk F. A. Wessels Jos Jonkers
author_sort	Stefano Annunziato
title	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
title_short	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
title_full	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
title_fullStr	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
title_full_unstemmed	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
title_sort	comparative oncogenomics identifies combinations of driver genes and drug targets in brca1-mutated breast cancer
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/d9ac65cbd345403caaf37726c9a7d740
work_keys_str_mv	AT stefanoannunziato comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT julianrderuiter comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT lindahenneman comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT chiarasbrambillasca comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT catrinlutz comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT francoisvaillant comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT federicaferrante comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT annepauliendrenth comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT elinevanderburg comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT bjørnsiteur comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT basvangerwen comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT roebidebruijn comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT martinehvanmiltenburg comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT ivojhuijbers comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT mariekevandeven comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT janeevisvader comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT geoffreyjlindeman comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT lodewykfawessels comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer AT josjonkers comparativeoncogenomicsidentifiescombinationsofdrivergenesanddrugtargetsinbrca1mutatedbreastcancer
_version_	1718382475592335360

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

Ejemplares similares